LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage improvement firm targeted on DNA-based immunotherapy and next-generation vaccines, introduced at present that the Firm will host a convention name at 11:00 a.m. EDT on Friday, March 19, 2021 to debate monetary outcomes for the yr ended December 31, 2020 and supply an replace on scientific improvement applications with GEN-1, a DNA-based immunotherapy for the localized therapy of ovarian most cancers and ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin beneath investigator-sponsored improvement for a number of most cancers indications. Celsion has two platform applied sciences for the event of novel nucleic acid-based immunotherapies and subsequent technology infectious vaccines. The Firm’s immunotherapy candidate, GEN-1, is at present in Part II improvement for the localized therapy of superior ovarian most cancers.
To take part within the name, events could dial 1-800-353-6461 (Toll-Free/North America) or 1-334-323-0501 (Worldwide/Toll) and ask for the Celsion Company Fourth Quarter 2020 Earnings Name (Convention Code: 1175518) to register ten minutes earlier than the decision is scheduled to start. The decision may also be broadcast reside on the web at www.celsion.com. The decision shall be archived for replay on Friday, March 19, 2021 and can stay accessible till April 2, 2021. The replay could be accessed at 1-719-457-0820 or 1-888-203-1112 utilizing Convention ID: 1175518. An audio replay of the decision may also be accessible on the Firm’s web site, www.celsion.com, for 90 days after 2:00 p.m. EDT Friday, March 19, 2021.
About Celsion Company
Celsion is a totally built-in, scientific stage biotechnology firm targeted on advancing a portfolio of modern most cancers remedies, together with immunotherapies and DNA-based therapies; and a platform for the event of nucleic acid vaccines at present targeted on SARS-CoV2. The corporate’s product pipeline consists of GEN-1, a DNA-based immunotherapy for the localized therapy of ovarian most cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is beneath investigator-sponsored improvement for a number of most cancers indications. Celsion additionally has two platform applied sciences for the event of novel nucleic acid-based immunotherapies and different anti-cancer DNA or RNA therapies. Each are novel artificial, non-viral vectors with demonstrated functionality in nucleic acid mobile transfection. For extra info on Celsion, go to www.celsion.com.
Ahead-looking statements on this information launch are made pursuant to the “protected harbor” provisions of the Non-public Securities Litigation Reform Act of 1995. These statements are topic to various dangers and uncertainties, lots of that are troublesome to foretell, together with, unexpected adjustments in the middle of analysis and improvement actions and in scientific trials; the uncertainties of and difficulties in analyzing interim scientific knowledge, notably in small subgroups that aren’t statistically important; FDA and regulatory uncertainties and dangers; the numerous expense, time and threat of failure of conducting scientific trials; the necessity for Celsion to judge its future improvement plans; potential acquisitions or licenses of different applied sciences, belongings or companies; potential actions by prospects, suppliers, opponents or regulatory authorities; and different dangers detailed on occasion within the Celsion’s periodic filings with the Securities and Alternate Fee. Celsion assumes no obligation to replace or complement forward-looking statements that grow to be unfaithful due to subsequent occasions, new info or in any other case.
Celsion Investor Contact
Jeffrey W. Church
LHA Investor Relations
Kim Sutton Golodetz